Eli Lilly said on Sept. 15 the U.S. government bought 388,000 additional doses of the company’s Covid-19 antibody therapy and Regeneron Pharmaceuticals said on Sept. 14 the U.S. government was buying 1.4 million additional doses of the Covid-19 antibody cocktail REGEN-COV., as infections surge due to the fast-spreading Delta variant.

CureVac said on Sept. 14 the German biotech firm cancelled contract manufacturing deals for the company’s experimental Covid-19 vaccine with two prospective partners, after rivals with approved shots boosted production.

ProQR Therapeutics is collaborating with Indianapolis-based Eli Lilly to bolster the Dutch biotechnology company’s Axiomer RNA editing platform and create new medicines that could treat a range of genetic disorders. 

Sanofi is investing more into its transplant operations through a $1.9 billion merger deal with Kadmon Holdings, another biopharma company that develops therapies for diseases with large unmet medical needs.

Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies.

Novartis AG said on Sept. 1 the company agreed on a deal with Britain’s healthcare service provider for use of the drugmaker’s new anti-cholesterol product Leqvio, after the country’s healthcare cost agency NICE approved the medicine.

Talkatoo, creators of the easy-to-use, efficient and platform-agnostic dictation software for animal health professionals, announced the closing of a new, oversubscribed round of funding led by Klick Ventures.

Vertex Pharmaceuticals and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.

Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.

International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.